AbbVie Deutschland GmbH & Co. KG

• A study to assess adverse events and effectiveness of upadacitinib oral tablets in adult and adolescent participants with vitiligo. Ended
  2023-506195-27-00 Phase III 11 countries UPADACITINIB
• A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalim… Ended
  2023-504598-18-00 Phase I 4 countries
• Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil… Ended
  2023-506029-12-00 Phase III 10 countries ATOGEPANT
• Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC): Evaluation of the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Co… Ended
  2022-502948-13-00 Phase II 3 countries BUDIGALIMAB; LENVATINIB; LIVMONIPLIMAB; SORAFENIB
• Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine… Ended
  2022-501172-25-00 Phase III 9 countries ATOGEPANT
• Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic … Ended
  2023-503655-10-00 Phase III 16 countries UPADACITINIB
• A Phase 3b/4 Randomized, Double-Blind, Double-Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib V… Ended
  2022-502578-18-00 Phase III/IV 11 countries ADALIMUMAB; UPADACITINIB
• A study to evaluate the dose optimization measures and safety of Etentamig (ABBV-383) in subjects with Relapsed or Refractory Multiple Myelo… Ended
  2023-504674-38-00 Phase I (Other) 3 countries
• This study is to find out about the Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in… Ended
  2023-505628-67-00 Phase III 14 countries EPCORITAMAB; LENALIDOMIDE; RITUXIMAB
• A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-… Ended
  2023-506871-88-00 Phase I (Other) 4 countries
• A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Participants Wit… Ended
  2023-507274-40-00 Phase I (Other) 6 countries NAVITOCLAX; RUXOLITINIB
• A Study to compare the efficacy of Risankizumab and Utsekinumab in Subjects with Moderately to Severe Active Crohns Disease Ended
  2022-501645-70-00 Phase III 14 countries RISANKIZUMAB; USTEKINUMAB
• Double-Blind study comparing venetoclax and azacitidine versus placebo and azacitidine in patients that are newly diagnosed with Higher-Risk… Ended
  2023-507153-16-00 Phase III 9 countries AZACITIDINE; VENETOCLAX
• Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Sub… Ended
  2023-508281-15-00 Phase I 6 countries BUDIGALIMAB; LIVMONIPLIMAB
• A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refra… Ended
  2023-505659-27-00 Phase II 2 countries CARFILZOMIB; DEXAMETHASONE; VENETOCLAX
• An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Ended
  2022-501522-38-00 Phase III 7 countries VENETOCLAX
• A study of IMGN632 alone or in combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia Ended
  2024-514197-50-00 Phase I/II 4 countries AZACITIDINE; PIVEKIMAB SUNIRINE; VENETOCLAX
• A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Respo… Ended
  2023-505477-33-00 Phase III 10 countries RISANKIZUMAB
• A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or … Ended
  2023-505478-14-00 Phase III 17 countries RISANKIZUMAB
• Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell … Ended
  2023-507902-15-00 Phase II 8 countries TELISOTUZUMAB VEDOTIN
• A study to test IMGN632 in adults with CD123-positive Acute Myeloid Leukemia and other CD123 positive Hematologic cancers. Ended
  2024-514195-40-00 Phase I (FiH) 2 countries PIVEKIMAB SUNIRINE
• Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Patients with Moderate to Severe Atopic Derma… Ended
  2022-502937-24-00 Phase III 18 countries UPADACITINIB
• A Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Ended
  2023-506994-36-00 Phase III 19 countries RISANKIZUMAB
• A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subject… Ended
  2023-506112-40-00 Phase III 7 countries POMALIDOMIDE; VENETOCLAX

Showing 73–96 of 138 trials